Disease | melanoma, malignant |
Symptom | C0220650|brain metastasis |
Sentences | 11 |
PubMedID- 26217117 | There are recent data using the anti-ctla-4 antibody ipilimumab at a dose of 10 mg/kg every 3 weeks for four cycles in melanoma patients with brain metastasis, with a response rate of 16% in asymptomatic and 5% in symptomatic patients. |
PubMedID- 25695690 | The efficacy of this agent in kit-altered melanoma with brain metastasis is limited. |
PubMedID- 24795353 | Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates. |
PubMedID- 26421283 | Temozolomide is an alkylating agent used in malignant brain tumors and in malignant melanoma (with brain metastasis). |
PubMedID- 20216240 | Anecdotal cases of partial or complete responses have been reported after ipilimumab therapy for stage iv melanoma with brain metastasis treated earlier by surgery or radiosurgery. |
PubMedID- 23392133 | Angiotropism in primary cutaneous melanoma with brain metastasis: a study of 20 cases. |
PubMedID- 23082737 | The high rate of brain metastasis in patients with advanced melanoma has been a clinical challenge for oncologists. |
PubMedID- 22577532 | brain metastasis is common in patients with melanoma and represents a significant cause of morbidity and mortality. |
PubMedID- 23824275 | Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients. |
PubMedID- 22488042 | The current analysis was conducted with samples from patients treated at a single institution, which pursues aggressive surgical and multimodality treatment of metastatic melanoma, including in patients with brain metastasis that could bias these results in a favorable manner. |
PubMedID- 24265631 | Notably, the finding that tcr gene-engineered t cells were able to traffic to the central nervous system and cause complete responses of brain metastasis in patients with melanoma was not only encouraging but also underscored the strength of t cell therapy toward metastasized and poorly accessible tumors (7). |
Page: 1